Perspective Therapeutics Posts 72% 18-Month PFS in VMT-α-NET Study UpdateMarketBeat · 2 days ago
Perspective's [212Pb]Bamzireotide Navoxetan (VMT-α-NET) Demonstrates Encouraging Safety, Durable Disease Control, and Robust Tumor Response Across Multiple Dose Cohorts in Phase 1/2a Trial in Advanced SSTR2-Expressing NETsGlobeNewsWire · 2 days ago
Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous TumorsGlobeNewsWire · Oct 8, 2026
Perspective Therapeutics (NYSEAMERICAN:CATX) Given “Buy” Rating at BTIG ResearchDefense World · Oct 7, 2026
Perspective Therapeutics Announces Acceptance of [212Pb]VMT-α-NET Data for Presentation at the NANETS 2026 Multidisciplinary NET Medical SymposiumGlobeNewsWire · Oct 7, 2026
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Stock Now Rated “Buy” by Sell-Side AnalystsDefense World · Oct 7, 2026Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 10, 2026 | -$0.25 | -$0.22 | Beat |
| May 11, 2026 | -$0.29 | -$0.25 | Beat |
| Mar 16, 2026 | -$0.37 | -$0.51 | Miss |
| Nov 10, 2025 | -$0.33 | -$0.35 | Miss |
| Aug 13, 2025 | -$0.30 | -$0.30 | Beat |
| May 12, 2025 | -$0.28 | -$0.25 | Beat |